Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

Twitter

⚑️ Checkmate 274 trial UPDATE at median follow-up 36.1 months. Median DFS 22.0 months Nivolumab vs 10.9 months w/pl… https://t.co/QmI9lwTUtd

  • 123456 Profile photo of Madelyn

    Interesting data after longer f/u from Checkmate 274 trial suggesting sustained DFS benefit with adjuvant nivo vs placebo in high risk resected urothelial Ca: the degree/magnitude of benefit was higher in PD-L1 >=1%; FDA approval regardless of PD-L1 status; no OS data yet since there has not been an adequate number of events